Introduction {#s1}
============

Colorectal cancer (CRC) is one of the most common type of malignancies, accounting for 1.8 million cases in GLOBOCAN 2018 ([@B1]). The incidence of CRC is increasing in China, where it ranks as the fifth most common carcinoma in male and the fourth in female, with a total of 215,700 patients diagnosed in 2015 ([@B2]). Epidemiologic investigations have attributed most of CRC to some important environmental factors ([@B3]). The increase of the incidence of CRC is proposed to correlate with an unhealthy lifestyle, including drinking, smoking, low intake of dietary fiber, high intake of dietary fat, decreased consumption of vegetables, and fruits and being physically inactive ([@B4]--[@B7]). Accumulating evidence highlighted that besides these unhealthy lifestyles and environmental factors, some additional inherited susceptibility factors may be associated with the development of CRC. As CRC is associated with obesity and Waist-to-Hip Ratio (WHR) ([@B8]--[@B10]), the *peroxisome proliferator-activated receptor gamma* (*PPARG*), *PPARG co-activator 1* (*PPARGC1*) family (e.g., *PPARGC1A* and *PPARGC1B*) may be strong candidate genes predisposing to CRC ([@B11]).

*PPARG* is located in 3p25. *PPARG* is also known as *NR1C3 (nuclear receptor subfamily 1, group C, member 3)* which shares some common conservative domains with other steroid receptors (e.g., estrogen, progesterone, retinoid, vitamin D and thyroid receptors). It was reported that *PPARG* is a regulator of adipocyte differentiation, energy homeostasis and obesity ([@B12]--[@B14]). *PPARG* decreases the inflammatory response of cells ([@B15]) and increases synthesis and release of paraoxonase 1 ([@B16]). Wang et al. reported that *PPARG* gene might be one of the targets of miRNA-34a and a conceivable therapeutic targets for CRC ([@B17]).^.^*PPARGC1A* and *PPARGC1B*, transcriptional co-activators of *PPARG*, may control transcription in adipogenesis, oxidative metabolism genes ([@B18]). Thus, *PPARG, PPARGC1A*, and *PPARGC1B* might be implicated in the development of cancer.

Pro12Ala and His449His (rs3856806 C\>T) polymorphisms in the *PPARG* gene are two of the most common variants in the *PPARG* gene. Recently, a meta-analysis confirmed that the *PPARG* Pro12Ala polymorphism might decreased the risk of CRC ([@B19]). Several case-control studies focused on the potential role of *PPARG* variants in determining CRC susceptibility. The *PPARG* rs3856806 C\>T is a common single-nucleotide polymorphism (SNP) in the coding region. Recently, a meta-analysis indicated that the *PPARG* rs3856806 C\>T polymorphism may increase the susceptibility of overall cancer ([@B20]). In this pooled study, there were seven independent case-control studies with 1,720 cases and 3,458 controls focusing on the association of the *PPARG* rs3856806 C\>T polymorphism with CRC risk ([@B21]--[@B24]). As well, a tendency to increased CRC susceptibility was noted. Because of the lack of sufficient sample sizes, the evidence may be limited. Additionally, ([@B25]) reported that the *PPARGC1B* rs7732671 G\>C polymorphism may decrease the susceptibility of breast cancer. However, the association between *PPARGC1A* and *PPARGC1B* SNPs and the risk of CRC was unknown. The aim of this case-control study was to assess the association of *PPARG, PPARGC1A*, and *PPARGC1B* polymorphisms with CRC risk. We selected *PPARG* rs3856806 C\>T, *PPARGC1A* rs2970847 C\>T, rs8192678 C\>T, rs3736265 G\>A, and *PPARGC1B* rs7732671 G\>C and rs17572019 G\>A SNPs to determine the relationship between their variants and CRC risk in an Eastern Chinese Han population.

Materials and Methods {#s2}
=====================

Study Subjects
--------------

This cohort was in part previously studied ([@B19], [@B26]). The CRC cases were recruited from Fujian Medical University Union Hospital (Fuzhou city, China) and the Affiliated People\'s Hospital of Jiangsu University (Zhenjiang city, China) between October 2014 and August 2017. The major inclusion criteria of CRC cases were: (1) sporadic CRC cases; (2) newly diagnosed CRC patients via pathology; and (3) Han population who living in Eastern China. And the exclusion criteria were: (1) hereditary non-polyposis CRC; (2) CRC cases who have been treated with chemoradiotherapy and (3) with another malignancy history. During the period, a total of 1,186 CRC patients were diagnosed in those local hospitals. Our study includes 1,003 (84.57%) patients, who agree to attend this study and provided blood samples for SNP analysis. The mean age of CRC patients was 61.10 ± 12.17 years. From 1,521 selected controls, 1,303 (85.67%) agreed to participate and donated a biological sample in this study. The controls included 1,303 healthy volunteers who participated in a routine examination in these hospitals, with a mean age of 61.40 ± 9.61 years. For selecting controls, the inclusion criteria were: (1) without a carcinoma history subjects; (2) similar age matched to CRC group; and (3) Han population who is a resident of Eastern China. Additionally, subjects who had a cancer history were excluded. The controls were matched with CRC patients by age and sex. The information on risk factor was obtained from the CRC cases and controls during a medical interview. And weight and height were measured. The body mass index (BMI) was calculated as weight/height^2^ (kg/m^2^) and BMI ≥ 24 kg/m^2^ was considered as overweight and obesity for Chinese ([@B27], [@B28]). All participants enrolled in the present study signed the informed consent and were of Chinese origin. The study protocol was approved by the Ethics Committee of Fujian Medical University and Jiangsu University.

DNA Extraction and Genotyping
-----------------------------

Two milliliters of Ethylenediamine tetra acetic acid (EDTA)-anticoagulated blood was collected from each participant. Blood samples were stored in a −80° C freezer. Using a Promega DNA Blood Mini Kit (Promega, Madison, USA), genomic DNA was isolated from lymphocytes. We placed the cryopreserved specimen at room temperature for an hour. After red blood cell removal, nuclear releasing and protein precipitation, we obtained genomic DNA. We add 300 μl of DNA solution (pH 8.0) and placed the sample in a refrigerator at 4°C for 1--2 weeks. A NanoDrop ND-1000 micro spectrophotometer was used to determine DNA concentration and purity. As described in previous studies, the genotypes of the *PPARG* rs3856806 C\>T, *PPARGC1A* rs2970847 C\>T, rs8192678 C\>T, rs3736265 G\>A, and *PPARGC1B* rs7732671 G\>C and rs17572019 G\>A SNPs was determined by a custom-by-design 48-Plex SNPscan Kit (Genesky Biotechnologies Inc., Shanghai, China) ([@B29], [@B30]). This genotyping method was designed as a multiplex fluorescence PCR ([@B31]). Ninety-two DNA samples (4%) were randomly selected and tested by another technician for quality control. The genotypes of these SNPs were not changed.

Statistical Analysis
--------------------

We used an online Chi-square software (<http://ihg.gsf.de/cgi-bin/hw/hwa1.pl>) to test deviation from the Hardy-Weinberg equilibrium (HWE) by using Pearson\'s goodness-of-fit chi-square. The genotype frequencies of the *PPARG* rs3856806 C\>T, *PPARGC1A* rs2970847 C\>T, rs8192678 C\>T, rs3736265 G\>A, and *PPARGC1B* rs7732671 G\>C and rs17572019 G\>A variants among CRC cases were compared to those of controls using a χ^2^ test or Fisher\'s exact test. Multivariate logistic regression analysis was harnessed to obtain crude and adjusted odds ratios (ORs) with their 95% confidence intervals (CIs) to predict the relationship of the *PPARG* rs3856806 C\>T, *PPARGC1A* rs2970847 C\>T, rs8192678 C\>T, rs3736265 G\>A, and *PPARGC1B* rs7732671 G\>C and rs17572019 G\>A polymorphisms with susceptibility to CRC. Dominant, recessive, heterozygote and homozygote models were used to evaluate the association of these SNPs with CRC risk. The χ^2^ test or Fisher\'s exact test was first applied to compare the distribution of age, sex, alcohol consumption, smoking status, and BMI between CRC patients and controls. A *P* \< 0.05 (two--tailed) was defined as a significant association. All data were analyzed by SAS software for Windows (9.4 version, SAS Institute, Cary, USA). In this case-control study, a Bonferroni correction test was applied for multiple testing ([@B32], [@B33]). An internal validation the through bootstrap method was applied to *PPARG* rs3856806 C\>T. We used 0.623 bootstrap method to resample 1,003 cases from the CRC patient group and 1,303 cases from the control group to validate our results.

Results {#s3}
=======

Study Characteristics
---------------------

Selected demographic variables and risk factors in the enrolled population and the correlation with CRC are summarized in [Table 1](#T1){ref-type="table"}. There was no significant difference between CRC patients and controls regarding sex (*P* = 0.867), age (61.10 ± 12.17 years for cases and 61.40 ± 9.61 years for controls, *P* = 0.496), suggesting that these variables were well-matched. Alcohol consumption, BMI and smoking status were statistically different (*P* \< 0.001, *P* \< 0.001, and *P* = 0.002, respectively) between two groups. The primary information of *PPARG, PPARGC1A*, and *PPARGC1B* SNPs is displayed in [Table 2](#T2){ref-type="table"}. The genotype distributions of *PPARG* rs3856806 C\>T, *PPARGC1A* rs2970847 C\>T, rs8192678 C\>T, rs3736265 G\>A, and *PPARGC1B* rs7732671 G\>C and rs17572019 G\>A are in accordance with HWE in controls (*P* = 0.143, 0.925, 0.800, 0.059, 0.970, and 0.372, respectively).

###### 

Distribution of selected characteristics in CRC cases and controls.

  **Variable**                **Cases (*n* = 1,003)**   **Controls (*n* = 1,303)**   ***P*[^a^](#TN1){ref-type="table-fn"}**           
  --------------------------- ------------------------- ---------------------------- ----------------------------------------- ------- --------------
  Age (years)                 62, IQR (53--70)                                       61, IQR (55--68)                                  
  Age (years)                                                                                                                          0.605
  \< 61                       451                       44.97                        600                                       46.05   
  ≥61                         552                       55.03                        703                                       53.95   
  **Sex**                                                                                                                              0.867
   Male                       620                       61.81                        801                                       61.47   
   Female                     383                       38.19                        502                                       38.53   
  **Smoking status**                                                                                                                   **0.002**
   Never                      744                       74.18                        1038                                      79.66   
   Ever                       259                       25.82                        265                                       20.34   
  **Alcohol use**                                                                                                                      **\< 0.001**
   Never                      829                       82.65                        1,167                                     89.56   
   Ever                       174                       17.35                        136                                       10.44   
  **BMI (kg/m**^**2**^**)**                                                                                                            
    \< 24                     670                       66.80                        688                                       52.80   **\< 0.001**
   ≥ 24                       333                       33.20                        615                                       47.20   
  **Site of tumor**                                                                                                                    
   Colon cancer               431                       42.97                                                                          
   Rectum cancer              572                       57.03                                                                          

*Two-sided χ^2^ test and student t-test*.

*IQR: interquartile range*.

*Bold values are statistically significant (P \< 0.05)*.

*BMI: body mass index*.

###### 

Primary information for *PPARG* rs3856806 C\>T, *PPARGC1A* rs2970847 C\>T, rs8192678 C\>T, rs3736265 G\>A, and *PPARGC1B* rs7732671 G\>C and rs17572019 G\>A polymorphisms.

  **Genotyped SNPs**                                                                            ***PPARG* rs3856806 C\>T**   ***PPARGC1A* rs2970847 C\>T**   ***PPARGC1A* rs3736265 G\>A**   ***PPARGC1A* rs8192678 C\>T**   ***PPARGC1B* rs7732671 G\>C**   ***PPARGC1B* rs17572019 G\>A**
  --------------------------------------------------------------------------------------------- ---------------------------- ------------------------------- ------------------------------- ------------------------------- ------------------------------- --------------------------------
  Chromosome                                                                                    3                            4                               4                               4                               5                               5
  Function                                                                                      coding-synonymous            coding-synonymous               missense                        missense                        missense                        missense
  Chr Pos (NCBI Build 38)                                                                       12434058                     23814301                        23813084                        23814039                        149832680                       149832908
  MAF[^a^](#TN2){ref-type="table-fn"} for Chinese in database[^b^](#TN3){ref-type="table-fn"}   0.25                         0.28                            0.23                            0.35                            0.09                            0.07
  MAF in our controls (*n* = 1,303)                                                             0.22                         0.22                            0.15                            0.44                            0.06                            0.06
  *P* value for HWE[^c^](#TN4){ref-type="table-fn"} test in our controls                        0.143                        0.925                           0.059                           0.800                           0.970                           0.372
  Genotyping method                                                                             SNPscan                      SNPscan                         SNPscan                         SNPscan                         SNPscan                         SNPscan
  \% Genotyping value                                                                           98.87%                       98.87%                          98.66%                          98.87%                          98.87%                          98.87%

*MAF: minor allele frequency*.

*<http://gvs.gs.washington.edu/GVS147/>*.

*HWE: Hardy--Weinberg equilibrium*.

Association of *PPARG* rs3856806 C\>T, *PPARGC1A* rs2970847 C\>T, rs8192678 C\>T, rs3736265 G\>A, and *PPARGC1B* rs7732671 G\>C and rs17572019 G\> A Polymorphisms With CRC Risk
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

[Table 3](#T3){ref-type="table"} summarizes the genotype distributions of *PPARG* rs3856806 C\>T, *PPARGC1A* rs2970847 C\>T, rs8192678 C\>T, rs3736265 G\>A, and *PPARGC1B* rs7732671 G\>C and rs17572019 G\>A SNPs in CRC cases and controls. The genotype frequencies of *PPARG* rs3856806 C\>T were 55.51% (CC), 38.16% (CT), and 6.33% (TT) in CRC cases and 60.69% (CC), 35.31% (CT), and 4.00% (TT) in controls. When the frequency of *PPARG* rs3856806 CC genotype was used as a reference, individuals carrying the *PPARG* rs3856806 TT genotype had an increased risk to CRC (crude OR = 1.67, 95% CI 1.13--2.45 for TT vs. CC, *P* = 0.009). When compared with the frequency of *PPARG* rs3856806 CC genotype, individuals carrying the *PPARG* rs3856806 TT/CT genotype also had an increased the risk of CRC (crude OR = 1.24, 95% CI 1.05--1.46 for TT/CT vs. CC, *P* = 0.013). When the frequency of the *PPARG* rs3856806 CC/CT genotype was used as a reference, individuals carrying the *PPARG* rs3856806 TT genotype had a significantly increased susceptibility to CRC (crude OR = 1.62, 95% CI 1.11--2.37 for TT vs. CC/CT, *P* = 0.012). After adjustments for age, sex, smoking, BMI, and drinking, the observed increased susceptibility of CRC was not essentially altered (TT vs. CC: adjusted OR, 1.59, 95% CI 1.08--2.35, *P* = 0.020; TT/CT vs. CC: adjusted OR, 1.26; 95% CI 95% CI 1.06--1.49; *P* = 0.009 and TT vs. CC/CT: adjusted OR, 1.54; 95% CI 95% CI 1.05--2.26; *P* = 0.028), [Table 3](#T3){ref-type="table"}.

###### 

Logistic regression analyses of associations between *PPARG* rs3856806 C\>T, *PPARGC1A* rs2970847 C\>T, rs8192678 C\>T, rs3736265 G\>A, and *PPARGC1B* rs7732671 G\>C and rs17572019 G\>A polymorphisms and risk of CRC.

  **Genotype**                         **Cases (*n* = 1,003)**   **Controls (*n* = 1,303)**   **Crude OR (95%CI)**   ***P***   **Adjusted OR^**a**^ (95%CI)**   ***P***                            
  ------------------------------------ ------------------------- ---------------------------- ---------------------- --------- -------------------------------- ----------- ---------------------- -----------
  ***PPARG*** **rs3856806 C\>T**                                                                                                                                                                   
  CC                                   544                       55.51                        789                    60.69     1.00                                         1.00                   
  CT                                   374                       38.16                        459                    35.31     1.14(0.96--1.35)                 0.145       1.16(0.97-1.39)        0.095
  TT                                   62                        6.33                         52                     4.00      **1.67(1.13--2.45)**             **0.009**   **1.59(1.08--2.35)**   **0.020**
  CT+TT                                436                       44.49                        511                    39.31     **1.24(1.05--1.46)**             **0.013**   **1.26(1.06--1.49)**   **0.009**
  CC+CT                                918                       93.67                        1,248                  96.00     1.00                                         1.00                   
  TT                                   62                        6.33                         52                     4.00      **1.62(1.11--2.37)**             **0.012**   **1.54(1.05--2.26)**   **0.028**
  T allele                             498                       25.41                        563                    21.65                                                                         
  ***PPARGC1A*** **rs2970847 C\>T**                                                                                                                                                                
  CC                                   593                       60.51                        788                    60.62     1.00                                         1.00                   
  CT                                   344                       35.10                        449                    34.54     0.98(0.83--1.17)                 0.855       0.97(0.81--1.16)       0.743
  TT                                   43                        4.39                         63                     4.85      0.88(0.59--1.31)                 0.520       0.92(0.61--1.38)       0.673
  CT+TT                                387                       39.49                        512                    39.38     1.00(0.85--1.19)                 0.959       1.00 (0.84--1.19)      0.985
  CC+CT                                937                       95.61                        1,237                  95.15     1.00                                         1.00                   
  TT                                   43                        4.39                         63                     4.85      0.90(0.61--1.34)                 0.610       0.95(0.63--1.42)       0.787
  T allele                             430                       21.94                        575                    22.12                                                                         
  ***PPARGC1A*** **rs3736265 G\>A**                                                                                                                                                                
  GG                                   685                       70.11                        936                    72.11     1.00                                                                
  GA                                   260                       26.61                        322                    24.81     1.07(0.88--1.29)                 0.493       1.06(0.87--1.29)       0.550
  AA                                   32                        3.28                         40                     3.08      1.06(0.66--1.70)                 0.813       1.04(0.64--1.68)       0.885
  GA + AA                              292                       29.89                        362                    27.89     1.10(0.92--1.32)                 0.297       1.09(0.91--1.31)       0.357
  GG+GA                                945                       96.72                        1,258                  96.92     1.00                                         1.00                   
  AA                                   32                        3.28                         40                     3.08      1.07(0.66--1.71)                 0.793       1.05(0.65--1.69)       0.854
  A allele                             324                       16.58                        402                    15.49                                                                         
  ***PPARGC1A*** **rs8192678 C\>T**                                                                                                                                                                
  CC                                   344                       35.10                        408                    31.38     1.00                                         1.00                   
  CT                                   454                       46.33                        645                    49.62     **0.79(0.66--0.95)**             **0.012**   **0.82(0.68--0.98)**   **0.033**
  TT                                   182                       18.57                        247                    19.00     0.83(0.65--1.05)                 0.113       0.85(0.66--1.08)       0.171
  CT+TT                                636                       64.90                        892                    68.62     0.85(0.71--1.01)                 0.062       0.87(0.73--1.05)       0.139
  CC+CT                                798                       81.43                        1,053                  81.00     1.00                                         1.00                   
  TT                                   182                       18.57                        247                    19.00     0.97(0.79--1.20)                 0.796       0.98(0.79--1.21)       0.832
  T allele                             818                       41.73                        1,139                  43.81                                                                         
  ***PPARGC1B*** **rs7732671 G\>C**                                                                                                                                                                
  GG                                   863                       88.06                        1,145                  88.08     1.00                                         1.00                   
  GC                                   113                       11.53                        150                    11.54     0.98(0.75--1.27)                 0.855       0.99(0.76--1.29)       0.924
  CC                                   4                         0.41                         5                      0.38      1.04(0.28--3.87)                 0.957       1.03(0.27--3.88)       0.967
  GC+CC                                117                       11.94                        155                    11.92     1.00(0.78--1.29)                 0.991       1.01(0.78--1.31)       0.927
  GG+GC                                976                       99.59                        1,295                  99.62     1.00                                         1.00                   
  CC                                   4                         0.41                         5                      0.38      1.06(0.28--3.96)                 0.929       1.05(0.28--3.96)       0.946
  C allele                             121                       6.17                         160                    6.15                                                                          
  ***PPARGC1B*** **rs17572019 G\>A**                                                                                                                                                               
  GG                                   862                       87.96                        1,144                  88.00     1.00                                                                
  GA                                   115                       11.73                        149                    11.46     1.00(0.77--1.30)                 0.998       1.02(0.79--1.33)       0.877
  AA                                   3                         0.31                         7                      0.54      0.56(0.14--2.15)                 0.395       0.47(0.12--1.84)       0.276
  GA+AA                                118                       12.04                        156                    12.00     1.00(0.78--1.30)                 0.976       1.02(0.78--1.32)       0.900
  GG+GA                                977                       99.69                        1,293                  99.46     1.00                                         1.00                   
  AA                                   3                         0.31                         7                      0.54      0.57(0.15--2.20)                 0.412       0.48(0.12--1.86)       0.286
  A allele                             121                       6.17                         163                    6.27                                                                          

*Adjusted for age, sex, smoking status, alcohol use and BMI status*.

*Bold values are statistically significant (P \< 0.05)*.

[Table S1](#SM1){ref-type="supplementary-material"} shows the internal validation results through the bootstrap method. When compared with the *PPARG* rs3856806 CC genotype, the *PPARG* rs3856806 TT, and TT/CT genotypes also indicate an increased CRC risk (crude OR = 1.56, 95% CI 1.09--2.23 for TT vs. CC, *P* = 0.015; crude OR = 1.20, 95% CI 1.02--1.42 for TT/CT vs. CC, *P* = 0.033). When compared with the *PPARG* rs3856806 CC/CT genotype, *PPARG* rs3856806 TT genotype also suggest an increased CRC risk (crude OR = 1.53, 95% CI 1.08--2.18 for TT vs. CC/CT, *P* = 0.017). After being adjusted by age, sex, smoking BMI, and drinking, the increased susceptibility of CRC was not essentially altered.

The genotype frequencies of *PPARGC1A* rs8192678 C\>T were 35.10% (CC), 46.33% (CT), and 18.57% (TT) in CRC patients and 31.38% (CC), 49.62% (CT), and 19.00% (TT) in healthy controls. When the frequency of the *PPARGC1A* rs8192678 CC genotype was used as a reference, individuals carrying the *PPARGC1A* rs8192678 CT genotype had a decreased susceptibility to CRC (crude OR = 0.79, 95% CI 0.66--0.95 for CT vs. CC, *P* = 0.012). After adjustments for age, sex, smoking, BMI and drinking, this association was also found (CT vs. CC: adjusted OR, 0.82; 95% CI 95% CI 0.68--0.989; *P* = 0.033), [Table 3](#T3){ref-type="table"}.

We found no significant difference in the genotype distribution of the *PPARGC1A* rs3736265 G\>A, rs2970847 C\>T and *PPARGC1B* rs7732671 G\>C, rs17572019 G\>A polymorphisms among CRC cases and controls, [Table 3](#T3){ref-type="table"}.

The Bonferroni correction test was applied to determine whether the association of the *PPARG* rs3856806 C\>T and rs8192678 C\>T polymorphisms with the risk of CRC was reliable. We defined the statistical significance level at 0.0125 (0.05/4 genetic models). We found the genotype distribution of that the *PPARG* rs3856806 C\>T polymorphism was still significantly different between CRC patients and controls (TT/CT vs. CC: adjusted OR, 1.26; 95% CI 95% CI 1.06--1.49; *P* = 0.009).

Association of *PPARG* rs3856806 C\>T Polymorphism With CRC Risk in a Stratified Analysis
-----------------------------------------------------------------------------------------

To further assess the association of the *PPARG* rs3856806 C\>T polymorphism with CRC risk, we conducted a stratified analysis by BMI, gender, age, tobacco using and alcohol consumption. [Table 4](#T4){ref-type="table"} presents the different genotype frequencies of the *PPARG* rs3856806 C\>T polymorphism in a subgroup analysis. After an adjustment by logistic regression analysis with gender, age, BMI, tobacco using and drinking status, we found that the *PPARG* rs3856806 C\>T polymorphism significantly increased the risk of CRC in several subgroups:1) male subgroup, TT vs. CC, adjusted OR = 1.88, 95% CI 1.14--3.10, *P* = 0.014 and TT vs. CT/CC, adjusted OR = 1.84, 95% CI 1.12--3.02, *P* = 0.016; 2) ≥61 years subgroup, CT/TT vs. CC, adjusted OR = 1.36, 95% CI 1.08--1.71, *P* = 0.010; 3) never smoking subgroup, CT/TT vs. CC, adjusted OR = 1.27, 95% CI 1.05--1.55, *P* = 0.015; 4) never drinking subgroup, CT/TT vs. CC, adjusted OR = 1.27, 95% CI 1.06--1.53, *P* = 0.011; 5) BMI ≥ 24 kg/m^2^ subgroup, TT vs. CC: adjusted OR = 2.65, 95% CI 1.36--5.17, *P* = 0.004; CT/TT vs. CC, adjusted OR = 1.38, 95% CI 1.05--1.81, *P* = 0.022, and TT vs. CT/CC, adjusted OR = 2.51, 95% CI 1.03--4.86, *P* = 0.006 ([Table 4](#T4){ref-type="table"}).

###### 

Stratified analyses between *PPARG* rs3856806 C\>T polymorphism and CRC risk by sex, age, BMI, smoking status, and alcohol consumption.

  **Variable**                ***PPARG*** **rs3856806 C\>T (case/control)[^a^](#TN6){ref-type="table-fn"}**   **Adjusted OR[^b^](#TN7){ref-type="table-fn"} (95% CI);** ***P***                                                                                                                                        
  --------------------------- ------------------------------------------------------------------------------- ------------------------------------------------------------------- ------- ------ ------------------------------ ------------------------------------------ ------------------------------------------- ------------------------------------------
  **SEX**                                                                                                                                                                                                                                                                                                              
  Male                        188/382                                                                         84/183                                                              15/22   1.00   1.13(0.90--1.41); *P*: 0.296   **1.88(1.14--3.10);** ***P*****: 0.014**   1.25(1.01--1.56); *P*: 0.042                **1.84(1.12--3.02);** ***P*****: 0.016**
  Female                      146/288                                                                         79/135                                                              9/19    1.00   1.23(0.92--1.64); *P*: 0.167   1.25(0.66--2.37); *P*: 0.487               1.26(0.96--1.67); *P*: 0.101                1.18(0.63--2.21); *P*: 0.603
  **AGE**                                                                                                                                                                                                                                                                                                              
  \< 61                       155/309                                                                         71/152                                                              12/14   1.00   1.06(0.81--1.38); *P*: 0.692   1.77(0.98--3.21); *P*: 0.060               1.15(0.89--1.49); *P*: 0.285                1.76(0.98--3.16); *P*: 0.060
  ≥61                         179/361                                                                         92/166                                                              12/27   1.00   1.27(1.00--1.61); *P*: 0.053   1.49(0.88--2.50); *P*: 0.135               **1.36 (1.08--1.71);** ***P*****: 0.010**   1.40(0.84--2.33); *P*: 0.202
  **SMOKING STATUS**                                                                                                                                                                                                                                                                                                   
  Never                       201/541                                                                         103/252                                                             13/34   1.00   1.20(0.98--1.47); *P*: 0.078   1.48(0.95--2.30); *P*: 0.082               **1.27(1.05--1.55);** ***P*****: 0.015**    1.41(0.91--2.17); *P*: 0.123
  Ever                        133/129                                                                         60/66                                                               11/7    1.00   1.03(0.71--1.48); *P*: 0.892   2.09(0.87--5.05); *P*: 0.100               1.17(0.82--1.67); *P*: 0.391                2.13(0.89--5.09); *P*: 0.088
  **ALCOHOL CONSUMPTION**                                                                                                                                                                                                                                                                                              
  Never                       283/623                                                                         139/287                                                             22/38   1.00   1.20(0.99--1.45); *P*: 0.067   1.48(0.97--2.26); *P*: 0.072               **1.27(1.06--1.53);** ***P*****: 0.011**    1.41(0.93--2.15); *P*: 0.108
  Ever                        51/47                                                                           24/31                                                               2/3     1.00   1.01(0.62--1.65); *P*: 0.969   2.59(0.89--7.54); *P*: 0.082               1.20(0.75--1.92); *P*: 0.445                2.62(0.91--7.52); *P*: 0.073
  **BMI (kg/m**^**2**^**)**                                                                                                                                                                                                                                                                                            
  \< 24                       210/353                                                                         107/171                                                             20/22   1.00   1.13(0.90--1.42); *P*: 0.296   1.26(0.78--2.03); *P*: 0.343               1.18(0.95--1.47); *P*: 0.131                1.23(0.77--1.96); *P*: 0.391
  ≥24                         124/317                                                                         56/147                                                              4/19    1.00   1.21(0.92--1.61); *P*: 0.177   **2.65(1.36--5.17);** ***P*****: 0.004**   **1.38(1.05--1.81);** ***P*****: 0.022**    **2.51(1.03--4.86);** ***P*****: 0.006**

*For PPARG rs3856806 C\>T, the genotyping was successful in 980 (97.71%) CRC cases, and 1300 (99.77%) controls*.

*Adjusted for multiple comparisons in a logistic regression model (age stratified analysis: sex, BMI, smoking status and alcohol consumption adjusted; sex stratified analysis: age, BMI, smoking status and alcohol consumption adjusted; BMI stratified analysis: age, sex, smoking status and alcohol consumption adjusted; smoking stratified analysis: age, sex, BMI and alcohol consumption adjusted and drinking stratified analysis: age, sex, BMI and smoking status adjusted)*.

*Bold values are statistically significant (P \< 0.05)*.

Association of *PPARG* rs3856806 C\>T Polymorphism With CRC in a Stratification Group by Site of Tumor
------------------------------------------------------------------------------------------------------

To determine whether the association between the *PPARG* rs3856806 C\>T polymorphism and CRC risk was modified by the site of CRC, we conducted stratified analyses. The results of the stratified analyses suggested this SNP increased the risk of colon cancer (CT vs. CC: adjusted OR = 1.27, 95% CI 1.01--1.60, *P* = 0.044 and TT/CT vs. CC: adjusted OR = 1.34, 95% CI 1.07--1.68, *P* = 0.011) and rectum cancer (TT vs. CC: adjusted OR = 1.58, 95% CI 1.01--2.49, *P* = 0.045 and TT vs. CC/CT: adjusted OR = 1.58, 95% CI 1.01--2.46, *P* = 0.043), [Table 5](#T5){ref-type="table"}.

###### 

Stratified analyses between *PPARG* rs3856806 C\>T polymorphism and CRC risk by site of tumor.

  **Genotype**                     **Controls (*n* = 1,303)**   **Colon cancer cases (*n* = 431)**   **Crude OR (95%CI)**   ***P***   **Adjusted OR[^a^](#TN10){ref-type="table-fn"} (95%CI)**   ***P*[^a^](#TN10){ref-type="table-fn"}**   **Rectum cancer cases (*n =* 572)**   **Crude OR (95%CI)**   ***P***   **Adjusted OR[^a^](#TN10){ref-type="table-fn"} (95%CI)**   ***P*[^a^](#TN10){ref-type="table-fn"}**                                      
  -------------------------------- ---------------------------- ------------------------------------ ---------------------- --------- ---------------------------------------------------------- ------------------------------------------ ------------------------------------- ---------------------- --------- ---------------------------------------------------------- ------------------------------------------ ----------- ---------------------- -----------
  ***PPARG*** **rs3856806 C\>T**                                                                                                                                                                                                                                                                                                                                                                                                                            
  CC                               789                          60.69                                228                    53.90     1.00                                                                                                  1.00                                                         316       56.72                                                      1.00                                                   1.00                   
  CT                               459                          35.31                                170                    40.19     1.24(0.99--1.56)                                           0.062                                      **1.27(1.01--1.60)**                  **0.044**              204       36.62                                                      1.06(0.86--1.31)                           0.564       1.08(0.88--1.34)       0.459
  TT                               52                           4.00                                 25                     5.91      1.61(0.98--2.66)                                           0.060                                      1.54(0.93--2.55)                      0.093                  37        6.64                                                       **1.70(1.10--2.65)**                       **0.018**   **1.58(1.01--2.49)**   **0.045**
  CT+TT                            511                          39.31                                195                    46.10     **1.32(1.06--1.65)**                                       **0.014**                                  **1.34(1.07--1.68)**                  **0.011**              241       43.27                                                      1.18(0.96--1.44)                           0.111       1.19(0.97--1.46)       0.099
  CC+CT                            1,248                        96.00                                398                    94.09     1.00                                                                                                  1.00                                                         520       93.36                                                      1.00                                                   1.00                   
  TT                               52                           4.00                                 25                     5.91      1.51(0.92--2.46)                                           0.101                                      1.43(0.87--2.34)                      0.160                  37        6.64                                                       **1.71(1.11--2.64)**                       **0.016**   **1.58(1.01--2.46)**   **0.043**
  T allele                         563                          21.65                                220                    26.00                                                                                                                                                                        278       24.96                                                                                                                                    

*Adjusted for age, sex, smoking status, alcohol use and BMI status*.

*Bold values are statistically significant (P \< 0.05)*.

Discussion {#s4}
==========

Accumulating evidence has highlighted that CRC is associated with obesity and Waist-to-Hip Ratio (WHR) ([@B8]--[@B10]). Some important metabolism-related genes may be strong candidates for predisposing to CRC ([@B11]). *PPARG* may be implicated in metabolism, inflammatory response, adipose cell differentiation, and cellular apoptosis ([@B34]--[@B37]). The *PPARGC1* family (e.g., *PPARGC1A, PPARGC1B*) also regulate fatty acid oxidation, gluconeogenesis and adaptive thermogenesis ([@B38]). These proteins may be involved in the development of obesity. Several studies have focused on the association between the *PPARG* rs3856806 C\>T polymorphism and the risk of CRC ([@B21]--[@B24]). However, the results were inconsistent. In addition, the potential relationships of the *PPARGC1A, PPARGC1B* SNPs with the development of CRC are unknown. To shed some light on this issue, we carried out a case-control study in Eastern Chinese Han population. Our findings suggested that the *PPARG* rs3856806 C\>T polymorphism is associated with an increased risk of CRC, especially in male, ≥ 61 years old, never smoking, never drinking, BMI ≥24 kg/m^2^, colon cancer, and rectum cancer subgroups.

*PPARG* is one of the three subtypes of *peroxisome proliferator-activated receptors (PPARs)*. The *PPARG* gene encodes a member of the *PPAR* subfamily of nuclear receptors, which form heterodimers with *retinoid X receptors (RXRs)* and then influence the transcription of many target genes. A previous study concluded that there was evidence for a relationship between obesity and overweight with a risk of colon and rectum cancer ([@B39]). A common functional polymorphism (His449His; rs3856806) in *PPARG* is a C → T coding-synonymous substitution in codon 449 of exon 6. Grygiel-Górniak and colleagues reported that higher BMI and visceral fat deposition were promoted by the presence of the *PPARG* rs3856806 T allele ([@B40]). Previous studies suggested a potential correlation of this SNP with atherosclerosis, type 2 diabetes and cancer ([@B20], [@B41]--[@B44]). Although rs3856806 is a coding-synonymous SNP, it is proposed that a C → T substitution could alter the expression of *PPARG* protein by altering mRNA processing or translation. Doecke et al. reported that the *PPARG* rs3856806 CT genotype may increase the susceptibility of adenocarcinoma of the esophagus in an obesity subgroup (BMI ≥ 30 kg/m^2^) ([@B45]). The *PPARG* rs3856806 C\>T polymorphism was also found to be significantly over-represented in sporadic glioblastoma multiforme in American populations ([@B46]). Jiang et al. reported that the *PPARG* rs3856806 C\>T polymorphism was associated with an increased risk of CRC in India ([@B21]). However, other case-control studies suggested that *PPARG* rs3856806 C\>T might not influence the development of CRC ([@B22]--[@B24]). Thus, the results were inconsistent and ambiguous. Considering a common SNP having low penetrance susceptibility to cancer, we performed a case-control study with large sample sizes to obtain a more precise assessment. As demonstrated in the results, we found that the *PPARG* rs3856806 C\>T polymorphism was associated with an increased risk of CRC, even after a Bonferroni correction test. Thus, our findings were reliable. Recently, a meta-analysis reported that the *PPARG* rs3856806 C\>T polymorphism increased the risk of overall cancer ([@B20]). Our findings were very similar to this pooled-analysis. Additionally, it is worth noting that we found the that the *PPARG* rs3856806 C\>T polymorphism was associated with an increased risk of CRC in the BMI ≥ 24 kg/m^2^ subgroup. It suggested that this SNP might be implicated in the development of obesity and overweight, and subsequently lead to an increased risk to CRC.

There are, however, several limitations in this case-control study. First, the CRC patients and non-cancer controls were from two local hospitals. The potential selection bias might have occurred. Second, a replicated study focusing on the association of these SNPs with CRC risk was not carried out. Third, although we took some risk factors into consideration such as BMI, gender, age, drinking, and smoking status, many other environmental and lifestyle factors, possibly related to the development of CRC, were not collected in this study. Fourth, due to the moderate sample size in some subgroups, the power might be limited. Fifth, a functional study for the *PPARG* rs3856806 C\>T polymorphism has not been conducted. Finally, in the future, it is necessary to carry out a functional study to identify the mechanism of the *PPARG* rs3856806 C\>T polymorphism.

In conclusion, our findings suggest that the *PPARG* rs3856806 C\>T polymorphism may increase the risk of CRC. In the future, larger sample size case-control studies with a detailed functional assessment are needed to further evaluate the relationship of *PPARG* rs3856806 C\>T polymorphism with CRC risk.
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